I’m thinking a bit of delay for GNBT. I could be wrong, and frequently am wrong, but in this case it would make sense that they gather up the results from the mouse analysis, prepare the IND accordingly, submit the IND and wait for the FDA green light...before another PR. Unless things have gone horribly wrong in the interim, they’ll be pursuing clinical trials no matter what the mice tell them. So the only important milestone will be the beginning of clinical trials. And that could be weeks.